Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about

< Previous 1 2 3 4 Next >
Biotech Company, ENDV Should Be On Everyone's Watchlist
From ACCESSWIRE
Innovative Biotech Companies Pushing the Envelope
From PR Newswire
Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the... 
From Business Wire News Releases
Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported pipeline... 
From Business Wire News Releases
Stock Review for Biotech's Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion Therapeutics
From PR Newswire
Market Trends Toward New Normal in Emerge Energy Services LP, NACCO Industries, 8x8, Eleven Biotherapeutics, Monolithic Power, and Highwoods Properties — Emerging Consolidated Expectations, Analyst Ra
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Emerge Energy Services LP... 
From GlobeNewswire News Releases
Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism
From PR Newswire
New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that... 
From Business Wire News Releases
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported key pipeline... 
From Business Wire News Releases
Small Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech Industry
From PR Newswire
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that... 
From Business Wire News Releases
Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EBIO, ECYT, ESPR, and EXEL which can be accessed for free by signing up to... 
From PR Newswire
Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market 
From Business Wire News Releases
Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the company... 
From Business Wire News Releases
Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
New Research Coverage Highlights Eleven Biotherapeutics, Enova International, Veracyte, Ameris, Veritiv, and United Fire Group — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eleven Biotherapeutics,... 
From GlobeNewswire News Releases
Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From GlobeNewswire News Releases
Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
New Research Coverage Highlights ConnectOne, Rockwell Medical, Accelerate Diagnostics, Eleven Biotherapeutics, Renasant, and Natera — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConnectOne Bancorp, Inc.... 
From GlobeNewswire News Releases
Eleven Biotherapeutics to Present at Biotech Showcase 2018
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
Eleven Biotherapeutics to Present at the LD Micro Main Event 2017
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today reported... 
From Business Wire News Releases
Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will... 
From Business Wire News Releases
Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that... 
From Business Wire News Releases
Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering
Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs)... 
From Business Wire News Releases
Eleven Biotherapeutics Prices of $8.0 Million Underwritten Public Offering
Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs)... 
From Business Wire News Releases
Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the... 
From Business Wire News Releases
Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that it... 
From Business Wire News Releases
Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform,... 
From Business Wire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.